标题
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
作者
关键词
-
出版物
JOURNAL OF ENDOCRINOLOGY
Volume 221, Issue 1, Pages T1-T16
出版商
Bioscientifica
发表日期
2013-12-10
DOI
10.1530/joe-13-0414
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
- (2013) Astrid Plamboeck et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity
- (2013) H. Schlogl et al. DIABETES CARE
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
- (2013) M. Pinget et al. DIABETES OBESITY & METABOLISM
- Nutrient control of hunger by extrinsic gastrointestinal neurons
- (2013) Gilles Mithieux TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Alterations in energy balance following exenatide administration
- (2012) David P. Bradley et al. Applied Physiology Nutrition and Metabolism
- Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling
- (2012) S. H. Lockie et al. DIABETES
- Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
- (2012) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- GLP-1 based therapies: differential effects on fasting and postprandial glucose
- (2012) M.S. Fineman et al. DIABETES OBESITY & METABOLISM
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Leptin therapy in type 2 diabetes
- (2012) B. P. Cummings DIABETES OBESITY & METABOLISM
- Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes
- (2012) Michael Horowitz et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice
- (2012) David Tweedie et al. EXPERIMENTAL NEUROLOGY
- Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
- (2012) Katherine M. Flegal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glucagon-like peptide-1 in the rat brain: Distribution of expression and functional implication
- (2012) Guibao Gu et al. JOURNAL OF COMPARATIVE NEUROLOGY
- The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors
- (2012) S. L. Dickson et al. JOURNAL OF NEUROSCIENCE
- The effect of glucagon-like peptide 1 on cardiovascular risk
- (2012) Jacob Sivertsen et al. Nature Reviews Cardiology
- Review article: the role of gastric motility in the control of food intake
- (2011) P. Janssen et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1
- (2011) Matthew R. Hayes et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans
- (2011) Akila De Silva et al. Cell Metabolism
- Metabolic and hedonic drives in the neural control of appetite: who is the boss?
- (2011) Hans-Rudolf Berthoud CURRENT OPINION IN NEUROBIOLOGY
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes: A randomized 26-week study on glycemic control and hypoglycemia
- (2011) B. Gallwitz et al. DIABETES CARE
- Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
- (2011) M. C. Bunck et al. DIABETES CARE
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
- (2011) David R. Whiting et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Changes in Differential Functional Magnetic Resonance Signals in the Rodent Brain Elicited by Mixed-Nutrient or Protein-Enriched Meals
- (2011) David K. Min et al. GASTROENTEROLOGY
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats
- (2011) Kansuke Fujiwara et al. JOURNAL OF NEUROCHEMISTRY
- Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
- (2011) A. M. Dossat et al. JOURNAL OF NEUROSCIENCE
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- GSK1614343, a Novel Ghrelin Receptor Antagonist, Produces an Unexpected Increase of Food Intake and Body Weight in Rodents and Dogs
- (2011) Vivian J.A. Costantini et al. NEUROENDOCRINOLOGY
- Reward Mechanisms in Obesity: New Insights and Future Directions
- (2011) Paul J. Kenny NEURON
- Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
- (2010) M. C. Bunck et al. DIABETES CARE
- Leptin and Amylin Act in an Additive Manner to Activate Overlapping Signaling Pathways in Peripheral Tissues: In vitro and ex vivo studies in humans
- (2010) H.-S. Moon et al. DIABETES CARE
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- (2010) Ulrich Werner et al. REGULATORY PEPTIDES
- Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea
- (2009) Richard Bergenstal et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- One-Year Treatment With Exenatide Improves -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial
- (2009) M. C. Bunck et al. DIABETES CARE
- Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study
- (2009) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide
- (2009) Renate E. van Genugten et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Homeostatic and Hedonic Signals Interact in the Regulation of Food Intake
- (2009) Michael Lutter et al. JOURNAL OF NUTRITION
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on “BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat,” by Bariohay et al.
- (2008) E. Fiona Bailey AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake
- (2008) D. A. Sandoval et al. DIABETES
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Brain Glucagon-Like Peptide 1 Signaling Controls the Onset of High-Fat Diet-Induced Insulin Resistance and Reduces Energy Expenditure
- (2008) Claude Knauf et al. ENDOCRINOLOGY
- Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
- (2008) Elisabeth B. Rüttimann et al. ENDOCRINOLOGY
- Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
- (2008) Diana L. Williams et al. ENDOCRINOLOGY
- Differential Sensitivity of Men and Women to Anorexigenic and Memory-Improving Effects of Intranasal Insulin
- (2008) Christian Benedict et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now